AXA Framlington Health Z Inc
Shares Class | Inc. |
---|---|
Yield | 0.23 |
Total Expense Ratio | 0.00 |
Fund Performance
Cumulative Performance
Discrete Performance
Shares Class | Inc. |
---|---|
Yield | 0.23 |
Total Expense Ratio | 0.00 |
Cumulative Performance
Discrete Performance
Fund Size | 578,197,300.00 | Launch Date | 27/02/1987 | Standard Initial Charge (%) | 0.00 |
---|---|---|---|---|---|
Currency | GBX | ISA Eligible | No | Annual Management Charge (%) | 0.75 |
Sector | IMA UK Equity Income | Min Investment (£) | 100,000.00 | Total Expense Ratio (%) | 0.00 |
ISIN | GB00BRJZVQ71 | Min Topup (£) | 5,000.00 | Ongoing Charge (%) | 0.8200 (on 19/02/2020) |
The Fund aims to provide long-term capital growth.
Dani Saurymper
Dani Saurymper joined AXA IM in April 2015 as fund manager for the AXA Framlington Health fund. He joined from Barclays Capital where he was a senior equity research analyst covering European Healthcare. Prior to this he covered global healthcare at Nomura as a sector specialist and was a senior pharmaceutical analyst at Goldman Sachs for nine years covering European Pharmaceuticals. Dani graduated from Leeds University with a BSc in Management Studies and Pharmacology and holds an MSc in International Business from the Manchester School of Management, UMIST.
Name | Weight |
---|---|
Europe ex UK Equities | 12.00% |
Japanese Equities | 2.00% |
Money Market | 0.00% |
North American Equities | 76.00% |
UK Equities | 7.00% |
Name | Weight |
---|---|
Europe ex UK | 12.00% |
Japan | 2.00% |
Money Market | 0.00% |
North America | 76.00% |
UK | 7.00% |
Name | Weight |
---|---|
Biotechnology/Medical | 6.00% |
Health Care | 2.00% |
Healthcare & Medical Products | 3.00% |
Hospital | 2.00% |
Money Market | 0.00% |
Pharmaceuticals | 35.00% |
Name | Weight |
---|---|
UNITEDHEALTH GROUP INC | 5.00% |
MERCK & CO INC(NEW) | 4.00% |
ROCHE HLDG AG | 4.00% |
ASTRAZENECA PLC | 3.00% |
HORIZON THERAPEUTICS PLC | 3.00% |
THERMO FISHER SCIENTIFIC INC | 3.00% |
ALEXION PHARMACEUTICALS INC | 2.00% |
MEDTRONIC INC | 2.00% |
PFIZER INC | 2.00% |
TAKEDA PHARMACEUTICAL CO | 2.00% |
Please remember that past performance is not a guide of future returns. The value of investments and the income from them can go down as well as up as a result of currency exchange and market fluctuations and investors may not get back the amount originally invested.